This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Steris (STE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add STERIS (STE) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about STERIS (STE) on its strong segmental growth in the third quarter of 2020.
5 Top S&P 500 Stocks That Rallied Last Week Defying Coronavirus
by Nalak Das
Despite coronovirus upsurge, a handful of S&P 500 stocks rallied last week. Some of them carry a favorable Zacks Rank with strong potential for future growth.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The coronavirus outbreak had an immaterial impact on Walgreens Boots' (WBA) second-quarter fiscal 2020 results.
Bruker (BRKR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Bruker's (BRKR) fourth-quarter 2019 results reflect strong performances by the majority of its segments and geographies.
STERIS' (STE) Organic Growth Robust Amid Bottom-Line Hurdles
by Zacks Equity Research
STERIS (STE) continues to register stellar organic growth across all four operating segments.
Neogen (NEOG) Q3 Earnings & Revenues Miss, Margins Decline
by Zacks Equity Research
Neogen's (NEOG) fiscal third-quarter 2020 results reflect strength in the Animal Safety segment.
Zacks.com featured highlights include: Medtronic, STERIS and Enova International
by Zacks Equity Research
Zacks.com featured highlights include: Medtronic, STERIS and Enova International
3 Top Stocks to Buy for Earnings Acceleration
by Tirthankar Chakraborty
Studies have shown that a majority of stocks had seen acceleration in earnings before a rally in stock price.
Steris (STE) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Rides on Robust Growth Across All Lines
by Zacks Equity Research
National Vision (EYE) continues to register strong segmental performances.
Here's Why You Should Add STERIS (STE) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about STERIS (STE) on its strong segmental performance in Q3.
STERIS (STE) Stock Hits New 52-Week High: What's Driving it?
by Zacks Equity Research
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with several tuck-in acquisitions.
STERIS' (STE) Growth Picture Impressive Amid Rising Costs
by Zacks Equity Research
STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.
Insulet (PODD) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) fourth-quarter 2019 results reflect strong segmental performances.
Intersect ENT (XENT) Reports Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Intersect ENT (XENT) exhibits a dismal performance in the fourth quarter of 2019.
Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Teleflex's (TFX) fourth-quarter 2019 results reflect strong segmental performances.
Integra (IART) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Integra's (IART) fourth-quarter 2019 results reflect strong segmental performances.
Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.
NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
NuVasive's (NUVA) Biologics business returns to growth in the fourth quarter of 2019.
Bruker (BRKR) Stock Rises on Strong Preliminary Q4 Show
by Zacks Equity Research
Bruker's (BRKR) revenue growth is expected to beat expectations for the fourth quarter and 2019.
Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up
by Zacks Equity Research
Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.
STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.